Applied DNA Sciences Inc. (APDN)
| Bid | 3.95 |
| Market Cap | 2.06M |
| Revenue (ttm) | 3.79M |
| Net Income (ttm) | -31.28M |
| EPS (ttm) | 3730.95 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.05 |
| Analyst | Buy |
| Ask | 4.02 |
| Volume | 25,094 |
| Avg. Volume (20D) | 145,519 |
| Open | 4.07 |
| Previous Close | 4.07 |
| Day's Range | 3.87 - 4.08 |
| 52-Week Range | 3.87 - 2655.00 |
| Beta | -0.04 |
About APDN
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for APDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · accessnewswire.com
Applied DNA Regains Compliance with All Nasdaq Continued Listing RequirementsSTONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received w...
1 month ago · accessnewswire.com
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. HaywardPresident and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or...
2 months ago · accessnewswire.com
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...
3 months ago · accessnewswire.com
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results- Therapeutic DNA Production Services Segment (LineaRx) Revenues Up 44% Y/Y, Contributing to a 6% Increase in Total Revenues - - Intra-Quarter Investor Conference Call and Webcast Scheduled for June ...